Alexion Pharmaceuticals Inc.

FCPA

SANCTION AMOUNT: $21476531

Defendants: Alexion Pharmaceuticals Inc.

Respondent agreed to settle charges that it violated the books and records and internal controls provisions of the Foreign Corrupt Practices Act, based on payments to government officials over roughly a 5-year span by Turkish and Russian subsidiaries to secure favorable treatment for Respondent’s primary drug, Soliris.

Key Docs
Official SEC press release

Find more cases

Named one of the top whistleblower practices/attorneys in the country by The New York Times, Wall Street Journal and NPR

Thank you for submitting some email to us.